Our Company

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody-drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine dimer technology.

Learn More ButtonLearn More Button

ADC Therapeutics Corporate Video

Our Pipeline

Proprietary PBD-based technology is the foundation for a diversified pipeline of ADCs in the treatment of hematological cancers and solid tumors.

View Pipeline ButtonPipeline View Button

Our Clinical Trials

Our PBD-based ADCs are advancing through clinical trials in multiple hematological and solid tumor indications.

Lead candidate Loncastuximab Tesirine (Lonca) is being evaluated in a pivotal phase 2 study in patients with relapsed or refractory DLBCL and ADCT intends to commence a phase 3 randomized study of Lonca in combination with rituximab versus immunochemotherapy.

Find Out More ButtonFind Out More Button


July 6, 2020

ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine


June 12, 2020

ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma


June 5, 2020

ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress